BETs that cover the spread from acquired to heritable heart failure.


Journal

The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877

Informations de publication

Date de publication:
01 09 2020
Historique:
pubmed: 11 8 2020
medline: 30 1 2021
entrez: 11 8 2020
Statut: ppublish

Résumé

Heart failure (HF) with reduced contractile function is a common and lethal syndrome in which the heart cannot pump blood to adequately meet bodily demands, resulting in high mortality despite the current standard of care. In modern societies, the most common drivers of HF are ischemic heart disease and hypertension. However, in a substantial subset of cases, patients present with dilated and poorly contracting hearts without evidence of common inciting stressors, a syndrome called dilated cardiomyopathy (DCM). Genome sequencing has identified a host of deleterious germline variants in key cardiomyocyte genes as causes of heritable DCM, including mutations in LMNA, which encodes the nuclear lamina-associated protein lamin A/C. In this issue of the JCI, Auguste et al. generate a mouse model of DCM in which they delete Lmna in cardiomyocytes and discover that bromodomain and extraterminal (BET) protein activation is a druggable epigenetic mechanism of disease pathogenesis in this heritable HF syndrome.

Identifiants

pubmed: 32773407
pii: 140304
doi: 10.1172/JCI140304
pmc: PMC7456232
doi:
pii:

Substances chimiques

Lamin Type A 0
Nuclear Proteins 0
Transcription Factors 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Comment

Langues

eng

Sous-ensembles de citation

IM

Pagination

4536-4539

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL127240
Pays : United States

Commentaires et corrections

Type : CommentOn

Références

J Mol Cell Cardiol. 2013 Oct;63:175-9
pubmed: 23939492
JCI Insight. 2020 Aug 6;5(15):
pubmed: 32603312
J Mol Cell Cardiol. 2019 May;130:197-204
pubmed: 30991033
Pharmacol Ther. 2020 Apr;208:107479
pubmed: 31931101
Sci Transl Med. 2017 May 17;9(390):
pubmed: 28515341
Nature. 2010 Dec 23;468(7327):1067-73
pubmed: 20871596
Nature. 2010 Dec 23;468(7327):1119-23
pubmed: 21068722
J Clin Invest. 2020 Sep 1;130(9):4740-4758
pubmed: 32484798
Circulation. 2020 Feb 4;141(5):387-398
pubmed: 31983221
Mol Cell. 2014 Oct 23;56(2):219-231
pubmed: 25263595
Curr Cardiol Rep. 2019 Nov 26;21(12):160
pubmed: 31773301
Mol Cell Biol. 2002 Jun;22(11):3794-802
pubmed: 11997514
Proc Natl Acad Sci U S A. 2017 May 16;114(20):E3993-E4001
pubmed: 28461486
Circ Res. 2019 Sep 13;125(7):662-677
pubmed: 31409188
Cell. 2017 Oct 19;171(3):573-587.e14
pubmed: 29033129
J Biol Chem. 2015 Apr 3;290(14):9111-21
pubmed: 25697361
Cell. 2013 Aug 1;154(3):569-82
pubmed: 23911322

Auteurs

Michael Alexanian (M)

Gladstone Institutes, San Francisco, California, USA.

Saptarsi M Haldar (SM)

Gladstone Institutes, San Francisco, California, USA.
Division of Cardiology, Department of Medicine, UCSF, San Francisco, California, USA.
Amgen Research, South San Francisco, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH